In the project: Personalized Medicine: Mycobacterium tuberculosis Drug Monitoring and Biomarker Analysis, we develop prevention and treatment strategies that take into account individual variability among people and allow predictions to accurately identify who will benefit most from specific therapies, while saving costs and side effects. In Heidelberg, we carry out the cost-effectiveness modelling studies to support the implementation considerations.
Phone: (++49) 6221 - 56 310787
dzif.heidelberg@med.uni-heidelberg.de
Department of Infectious Diseases
Im Neuenheimer Feld 344
69120 Heidelberg, Germany